World Journal of Gastrointestinal Oncology最新文献

{"title":"SAC3 domain containing 1 intervention in energy metabolism reprogramming assists in the progression of hepatocellular carcinoma.","authors":"Xue-Jing Lin, Er-Jiang Tang, Bin Sun, Ai-Li Wang, Ying Chen, Lei Chen, Yi-Yang Xue, A-Jian Li, Chun-Ying Liu","doi":"10.4251/wjgo.v17.i7.107971","DOIUrl":"10.4251/wjgo.v17.i7.107971","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysregulation is considered a significant hallmark of hepatocellular carcinoma (HCC). SAC3 domain containing 1 (SAC3D1) functions in the cell cycle, and its expression is upregulated in various cancers. It is known that metabolic changes occur at different stages of the cell cycle to maintain the biosynthesis and replication of both normal and cancer cells. Based on the role of SAC3D1 in mitosis, we hypothesize that abnormal expression of SAC3D1 may affect cellular metabolism. However, it remains unclear whether SAC3D1 mediates the progression of HCC by regulating metabolic reprogramming.</p><p><strong>Aim: </strong>To comprehensively elucidate the impact and molecular mechanism of SAC3D1 on the progression of HCC by regulating the metabolic reprogramming.</p><p><strong>Methods: </strong>The constructed SAC3D1 overexpression and knockdown HCC cell lines were used for detecting cell proliferation, migration capabilities, as well as glycolysis and adenosine triphosphate (ATP) production rate assays. They were also employed for examining molecular markers associated with cell migration and glycolysis. The transcriptome sequencing data of cells have revealed the pathways potentially influenced by SAC3D1.The tail vein metastasis model and xenograft tumor experiments were utilized to demonstrate SAC3D1's tumor-promoting effects <i>in vivo</i>.</p><p><strong>Results: </strong>SAC3D1 expression was upregulated and associated with poor prognosis in HCC patients. SAC3D1 enhanced the proliferation and migration abilities and reduced the population dependence of HCC cells <i>in vitro</i> and <i>in vivo</i>. The upregulation of SAC3D1 enhanced cellular glycolysis and ATP production. The cell transcriptome sequencing data revealed that SAC3D1 activated Wnt signaling pathway. SAC3D1 did not modulate the transcription of <i>β-Catenin</i>, while might inhibit its degradation. Further investigations indicated that the increase of SAC3D1 leads to more β-Catenin accumulating in the nucleus, facilitating the expression of c-Myc, one of the upstream regulatory factors of glycolysis. The iCRT3, an antagonist of β-Catenin, could counteract the increase of c-Myc induced by SAC3D1, while also downregulating the expression of glycolysis-related proteins.</p><p><strong>Conclusion: </strong>This study found that SAC3D1 enhances HCC cell glycolysis and ATP production <i>via</i> the β-Catenin/c-Myc signaling axis, thereby promoting the progression of HCC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"107971"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells.","authors":"Meng-Yan Chen, Chen Wang, Yu-Gang Wang, Min Shi","doi":"10.4251/wjgo.v17.i7.106723","DOIUrl":"10.4251/wjgo.v17.i7.106723","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common cancer worldwide and remains a major treatment challenge, particularly in advanced and metastatic stages. Current standard treatments have limited efficacy, underscoring the urgent need for innovative strategies. Adoptive cell therapy (ACT), which involves <i>in vitro</i> expansion or genetic engineering of immune cells, is a promising approach to bolster anti-tumor immune responses. Key ACT modalities include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has shown success in hematological malignancies but faces significant challenges in solid tumors like CRC. These challenges include antigen heterogeneity, an immunosuppressive tumor microenvironment, on-target off-tumor toxicity, among other factors. To address these limitations, combinatorial approaches, such as immune checkpoint inhibitors, cytokines, and advanced gene-editing tools like CRISPR/Cas9, are being actively explored. These strategies aim to enhance CAR-T cell specificity, improve resistance to immunosuppressive signals, and optimize <i>in vivo</i> functionality. This review summarizes ACT approaches for CRC, with a focus on CAR-T therapy. It briefly introduces TILs and TCR-T cells, while emphasizing the major challenges faced by CAR-T therapy in solid tumors and discusses potential strategies to improve therapeutic outcomes.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"106723"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Prohibitin 1 inhibits cell proliferation and induces apoptosis <i>via</i> the p53-mediated mitochondrial pathway <i>in vitro</i>.","authors":"Juan-Juan Shi, Shuang-Suo Dang","doi":"10.4251/wjgo.v17.i7.110127","DOIUrl":"10.4251/wjgo.v17.i7.110127","url":null,"abstract":"<p><p>[This corrects the article on p. 398 in vol. 16, PMID: 38425403.].</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"110127"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of radiotherapy on lymphocytes in patients with middle and lower esophageal cancer and its relationship with prognosis.","authors":"Shu-Guang Li, Yang Liu, Xue-Yuan Zhang, You-Mei Li, Wen-Bin Shen, Shu-Chai Zhu","doi":"10.4251/wjgo.v17.i7.108205","DOIUrl":"10.4251/wjgo.v17.i7.108205","url":null,"abstract":"<p><strong>Background: </strong>Definitive chemoradiotherapy is the standard treatment for unresectable, locally advanced esophageal cancer. However, radiotherapy (RT) often affects the immune system of patients. One of the possible mechanisms of lymphopenia after RT is that a large number of circulating lymphocytes in the systemic and pulmonary circulation will be killed by more sessions of low-dose radiation. The impact of dose-volume parameters of organs at risk (OARs) on absolute lymphocyte count (ALC) and the relationship between the extent of lymphocyte count reduction and survival prognosis in patients with middle and lower thoracic esophageal squamous cell carcinoma (ESCC) both remain difficult to determine.</p><p><strong>Aim: </strong>To determine the relationship between RT parameters, lymphocyte count and survival prognosis of esophageal cancer patients.</p><p><strong>Methods: </strong>The clinical data of 112 patients with stage I-III ESCC who received definitive RT were analyzed retrospectively. The ALC values before RT, weekly during RT, and within 1 month after RT were determined. Logistic regression was used to evaluate the correlation between the parameters of radiation OARs and the lowest point of the ALC. Kaplan-Meier and Cox regression analyses were used to evaluate the relationship between the lowest point of the ALC and patient survival during RT.</p><p><strong>Results: </strong>The median value of the ALC before treatment was 1.57 × 10⁹ cells/L, and 32 patients (28.6%) showed grade 4 ALC reduction during RT. The reduction in G4 ALC during RT was significantly associated with poor overall survival (OS) and progression-free survival. Multivariate analysis showed that stage III tumors (<i>P</i> = 0.003), high heart V₁₀ (<i>P</i> = 0.046), high lung V₅ (<i>P</i> = 0.048), and high lung V₂₀ (<i>P</i> = 0.031) were associated with G4 ALC reduction during RT.</p><p><strong>Conclusion: </strong>The reduction in G4 ALC is related to OS. Joint evaluation of the tumor stage and dose volume parameters has predictive value for G4 ALC reduction and OS.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"108205"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of a nomogram model for treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.","authors":"Qiong-Ya Guo, Wei Zhang, Lin Fu, Shan-Shan Hu, Lin Li","doi":"10.4251/wjgo.v17.i7.105403","DOIUrl":"10.4251/wjgo.v17.i7.105403","url":null,"abstract":"<p><strong>Background: </strong>Locally advanced rectal cancer (LARC) carries a substantial risk of recurrence, prompting the use of neoadjuvant chemoradiotherapy (nCRT) to improve tumor resectability and long-term outcomes. However, individual treatment responses vary considerably, highlighting the need for robust predictive tools to guide clinical decision-making.</p><p><strong>Aim: </strong>To develop a nomogram model integrating clinical characteristics and biomarkers to predict the likelihood of poor response to nCRT in LARC.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 178 patients with stage II-III LARC treated from January 2021 to December 2023. All patients underwent standardized nCRT followed by total mesorectal excision. Clinical data, inflammatory markers [C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha], and tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 19-9] were collected. Logistic regression was used to identify independent predictors of poor nCRT response. A nomogram was constructed using significant predictors and validated <i>via</i> concordance index (C-index), receiver operating characteristic curve, calibration plot, and decision curve analysis (DCA).</p><p><strong>Results: </strong>A total of 178 patients were enrolled, with 36 (20.2%) achieving a good response and 142 (79.8%) exhibiting a poor response to nCRT. Baseline factors, including age and comorbidities, showed no significant differences. However, poor responders more frequently had lymph node metastasis, advanced tumor node metastasis/T stage, larger tumor diameter, and elevated CRP, IL-6, and CEA levels. Logistic regression confirmed CRP, IL-6, and CEA as independent predictors of poor response. The nomogram demonstrated high accuracy (area under the curve = 0.928), good calibration (Hosmer-Lemeshow <i>P</i> = 0.928), and a sensitivity of 88.1% with 82.6% specificity. Internal validation <i>via</i> bootstrap resampling (<i>n</i> = 1000) yielded an adjusted C-index of 0.716, and DCA confirmed substantial clinical utility.</p><p><strong>Conclusion: </strong>A nomogram incorporating serum CRP, IL-6, and CEA accurately predicts poor nCRT response in patients with LARC. This model provides a valuable framework for individualized treatment planning, potentially improving clinical outcomes.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"105403"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of neutrophil-to-lymphocyte ratio combined with carcinoembryonic antigen in postoperative adjuvant chemotherapy after gastric cancer surgery.","authors":"Yuan-Zheng Zhao, Jia-Qi Han, Xin-Ran Zhao, Zi-Yuan Wang, Kai-Yu He, Yong-Sheng Duan, Hong-Xia Lu","doi":"10.4251/wjgo.v17.i7.107399","DOIUrl":"10.4251/wjgo.v17.i7.107399","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is an aggressive malignancy of the gastrointestinal tract characterized by high recurrence rates following radical gastrectomy. To enhance treatment efficacy, reduce recurrence, and improve patient survival, adjuvant chemotherapy is commonly administered based on established postoperative guidelines. Despite advancements in chemotherapy delivery, the overall response rate remains below 50%, primarily due to the lack of targeted therapies tailored to specific patient populations.</p><p><strong>Aim: </strong>To explore sensitive biomarkers to assess the efficacy of postoperative adjuvant chemotherapy in appropriate patient subgroups.</p><p><strong>Methods: </strong>This study retrospectively analyzed 1628 patients who underwent radical gastrectomy for GC at our hospital in 2017 and 2018, with a subsequent five-year follow-up. Patients were divided based on whether they received postoperative adjuvant chemotherapy. The study aimed to determine optimal cutoff values for various biomarkers-neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 199, CA724, and CA242-using receiver operating characteristic (ROC) curves. Based on the optimal ROC cut-off, a novel combined metric, NLR-CEA, was developed to assess the efficacy of adjuvant chemotherapy following GC surgery.</p><p><strong>Results: </strong>Cox subgroup analysis demonstrated that postoperative adjuvant chemotherapy significantly improved overall survival in the NLR-CEA_Low group with a rate of 0.41 (0.26-0.63). In the NLR-CEA_Middle group, the protective effect was observed at 0.69 (0.54-0.87), while in the NLR-CEA_High group, it was 0.73 (0.53-0.99). Notably, a 32% difference in the efficacy of chemotherapy was observed between the NLR-CEA_Low and NLR-CEA_High groups.</p><p><strong>Conclusion: </strong>NLR-CEA is an effective biomarker for evaluating the efficacy of postoperative adjuvant chemotherapy in GC. Patients with NLR-CEA_Low exhibit significantly better responses to chemotherapy compared to those with NLR-CEA_High.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"107399"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of interleukins in the pathogenesis of cholangiocarcinoma: A literature review.","authors":"Saira Rafaqat, Hafsa Hamid, Roha Asif, Muhammad Asif, Maria Tariq, Malaika Saleem, Hijab Abaid","doi":"10.4251/wjgo.v17.i7.107341","DOIUrl":"10.4251/wjgo.v17.i7.107341","url":null,"abstract":"<p><p>This article summarized the role of interleukins (ILs) in the pathogenesis of cholangiocarcinoma (CCA). It discovered a negative feedback mechanism wherein alternative splicing led to the upregulation of the IL 1 receptor antagonist (IL1RN) isoforms IL1RN-201 and IL1RN-203, which play a crucial anti-inflammatory role in <i>KRAS</i>-mutant intrahepatic CCA (iCCA). Higher levels of IL-4 receptor were associated with a worse survival rate in patients with CCA. In addition, elevated levels of serum IL-6 have been associated with the start and progression of CCA, a common cancer generated by inflammation. IL-8 was a useful predictor of human hilar CCA. Mechanistically, signal transducer and activator of transcription 3 signaling was used by IL-10 produced from M2-polarized tumor-associated macrophages to enhance the malignant characteristics of iCCA cells. It was suggested that IL-17A and IL-22 have an impact on the development of CCA associated with hepatic fluke infection. The most significant finding was the decreased expression of the IL-23 receptor, a prognostic gene, in iCCA. IL-25 may be a useful prognostic biomarker as aberrant expression of the protein in CCA tissue was linked to tumor spread and a poor prognosis. Tumor cell migration and proliferation were both accelerated by homogenized liver tissue that expressed IL-33 significantly. The correlation between high IL-35 expression and aggressiveness in iCCA highlights it as a useful biomarker for assessing the course and prognosis of iCCA in clinical settings. This article concluded that IL-1, IL-4, IL-6, IL-8, IL-10, IL-17, IL-23, IL-25, IL-33, and IL-35 play significant roles in the pathogenesis of CCA. Further research is required to find the association of other ILs such as IL-2, IL-3, IL-5, IL-7, IL-11, and more in the pathogenesis of CCA.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"107341"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound diagnosis of small bowel adenocarcinoma in Crohn's disease: A case report and review of literature.","authors":"Min-Ying Zhong, Guo-Liang Jian, Jie-Yi Ye, Ke-Xin Chen, Wei-Jun Huang","doi":"10.4251/wjgo.v17.i7.108258","DOIUrl":"10.4251/wjgo.v17.i7.108258","url":null,"abstract":"<p><strong>Background: </strong>Crohn's disease (CD)-related small bowel adenocarcinoma (SBA) is a rare adenocarcinoma that is difficult to detect and diagnose in its early stages and is associated with long-standing inflammation, which may predispose patients with CD to SBA. This case report describes a patient with CD who was diagnosed with SBA using intestinal ultrasonography (IUS).</p><p><strong>Case summary: </strong>A 38-year-old male diagnosed with CD since 23 years of age was maintained in remission with mesalamine, although he did not take his medication regularly. The patient presented with recurrent dull abdominal pain, bloating, and a three-month history of diarrhea (3 times per day) with unformed stools. Abdominal examination revealed mildly diffuse tenderness. IUS revealed eccentric thickening (23 mm) in the terminal ileum. The hierarchical structure of the intestinal wall disappeared, revealing the \"pseudo-kidney\" sign. A stricture was identified in the terminal ileum with dilation of the proximal intestinal tract. Color Doppler flow imaging revealed linear blood flow. Contrast-enhanced ultrasound revealed highly heterogeneous enhancement with rapid washout in ileocecal junction, suggesting malignant transformation of CD with intestinal obstruction. Pathological examination revealed poorly differentiated adenocarcinoma of the ileocecal junction.</p><p><strong>Conclusion: </strong>Active surveillance for SBA using IUS is prudent, given its advantages of real-time dynamic imaging, high-detail resolution, and low cost.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"108258"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of immune-inflammation and nutritional indices in advanced hepatocellular carcinoma patients receiving immunotherapy with compound Kushen injection.","authors":"Yong-Fu Zhu, Dong-Wei Zhang, Ming Zhang, Ming-Hui Yu, Shao-Hu Zhang, Yue-Yue Wu","doi":"10.4251/wjgo.v17.i7.106684","DOIUrl":"10.4251/wjgo.v17.i7.106684","url":null,"abstract":"<p><strong>Background: </strong>Advanced hepatocellular carcinoma (HCC) with ascites (AS) lacks reliable biomarkers for predicting treatment outcomes. The combined prognostic value of the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) remains underexplored for novel therapies.</p><p><strong>Aim: </strong>To evaluate the clinical efficacy of combining intraperitoneal compound Kushen injection (CKI) with immunotherapy in patients with advanced HCC using a scoring system that combines SII and PNI.</p><p><strong>Methods: </strong>SII and PNI were calculated prior to treatment from peripheral blood samples, and critical values were determined by receiver operating characteristic analysis. SII-PNI scores were categorized as follows: 2, high SII (≥ 558.5) and low PNI (≤ 33.58); 1, high SII or low PNI; and 0, neither high SII nor low PNI. After immunotherapy combined with CKI, patients with advanced HCC were evaluated using the SII-PNI scoring criteria.</p><p><strong>Results: </strong>The SII-PNI score was significantly lower in patients without concomitant AS than in those with AS (<i>P</i> = 0.017). Progression-free survival was significantly longer in patients with a low SII-PNI score than in those with a high SII-PNI score (<i>P</i> = 0.0125). Multivariate analysis identified the SII-PNI score as an independent prognostic factor for 2-year overall survival in patients with advanced HCC and AS (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>The pretreatment SII-PNI score is an important indicator of treatment sensitivity for patients with advanced HCC receiving intraperitoneal CKI. It also represents a crucial basis for evaluating treatment efficacy and prognosis, aiding in the identification of high-risk groups and prognosis prediction.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"106684"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144709156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult pancreatoblastoma: Systematic review of the literature and case report of a young adult patient.","authors":"Jacob T Harris, Steve Gurley, Erkut Borazanci","doi":"10.4251/wjgo.v17.i7.106701","DOIUrl":"10.4251/wjgo.v17.i7.106701","url":null,"abstract":"<p><strong>Background: </strong>Adolescent/adult pancreatoblastoma (PB) is an uncommon malignant pancreatic tumor. The paucity of data stemming from the rarity of this disease leads to minimal generalized guidelines regarding its diagnosis and treatment. There is a limited number of case reports in the literature and there has been no recent analysis of the literature to consolidate their common features. The purpose of the featured study is to review the available cases of adolescent/adult PB and analyze the common genetic features, histologic features, treatment regimens, tumor sizes, tumor locations, and areas of metastasis to advance ongoing research and better understand and treat this rare condition.</p><p><strong>Aim: </strong>To present a patient case and systematically review all available cases in the literature to consolidate the common physical, genetic, and histologic features of PB.</p><p><strong>Methods: </strong>This is a systematic review of the literature with a case study. A total of 89 patient cases were discovered in the literature database for adolescent/adult PB, all of which were reviewed and are included in our research. Patients aged 16-18 were considered adolescent and patients aged greater than 18 were considered adult. Adolescents and adults were grouped together for the purpose of this study. The patient from the case report was seen in a community hospital setting.</p><p><strong>Results: </strong>The 89 cases analyzed from the literature were found in 51 references (our case report included), which were consolidated into the six categories mentioned above. A plurality of references reports PB in the head of the pancreas, 4.0-10.0 cm in size, and with the most common site of metastasis to the liver. Histology studies most commonly included acinar groups, squamous corpuscles/nests, cytokeratin, chromogranin, trypsin, chymotrypsin, and synaptophysin. Genetic studies most commonly included adenomatous polyposis coli, B-cell lymphoma/leukemia 10, catenin beta 1, and Wnt/beta-catenin mutations. The mainstay of treatment was surgery with chemotherapy typically including cisplatin, carboplatin, doxorubicin, 5 fluorouracil, mitomycin, bleomycin, gemcitabine, and vindesine. Radiation was also often used.</p><p><strong>Conclusion: </strong>Common pancreatoblastoma features include acinar groups, chromogranin, chymotrypsin, squamous corpuscles, synaptophysin and trypsin on histology and adenomatous polyposis coli, B-cell lymphoma/leukemia 10, catenin beta 1, and Wnt/beta-catenin genetic mutations.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"106701"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}